首页 >
法规速递
-
国家药监局关于修订盐酸消旋山莨菪碱注射制剂说明书的公告（2026年第17号）-2026/2/9
2026-02-10查看详情 > -
Document: Questions and answers on the refusal of a change to the marketing authorisation for Hetlioz (tasimelteon) (II-40)-2026/3/17
2026-03-18查看详情 > -
Document: Agenda of the CHMP meeting 20-23 April 2026-2026/4/20
2026-04-21查看详情 > -
国家药监局药审中心关于发布《咀嚼片（化学药品）质量属性研究技术指导原则（试行）》的通告（2023年第7号）-2023/02/14
2023-02-14查看详情 > -
Draft Guidance: Post-Warning Letter Meetings Under GDUFA-2023/9/1
2023-09-04查看详情 > -
Considerations for Complying with 21 CFR 211.110-2025/1/6
2025-01-06查看详情 > -
Page: Medicine shortages and availability issues-2025/2/6
2025-02-10查看详情 > -
Document: Product Management Service (PMS) roadmap-2025/3/14
2025-03-17查看详情 > -
Page: Fees payable to the European Medicines Agency: Fees, charges and remuneration for assessment procedures and services relating to veterinary medicinal products-2025/4/15
2025-04-16查看详情 > -
国家药监局关于发布麻醉药品和精神药品实验研究管理规定的公告（2025年第51号） -2025/5/30
2025-05-30查看详情 >
